Protocol No.: M19-973

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)
Principal Investigator
Zinn, Zachary
Phase
III
Age Group
Children
Applicable Disease Site
Other
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Erica Blystone, RN
Clinical Research Specialist
Phone: +1 304-293-3415

View on ClinicalTrials.gov